US4270924A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Diagnostic method for detecting cancer
Assignee: Baylor College of Medicine
•
Filing: 1980-03-13
•
Granted: 1981-06-02
•
Expires: 2000-03-13
Abstract
Abstract Diagnostic method for detecting cancer in humans comprising assaying a serum sample for concentration of a particular DNA-binding protein. The concentration of this serum protein has been found to be significantly different in patients having cancer than in cancer-free patients.
Inventors
- 👤 Stanley T. Crooke
- 👤 Louis Galvan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 11:39
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/5308; G01N33/52; G01N33/575; G01N33/5755; G01N33/5758; G01N33/57585; G01N33/68; G01N33/6875; G01N2333/00; G01N2333/435; G01N2333/46; G01N2333/47; G01N2333/4701; G01N2333/4703; G01N2333/4704; G01N2333/475; G01N2333/50
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
78 words
A method for detecting cancer in humans which comprises the steps of (a) obtaining a blood sample from a patient to be screened for cancer; (b) determining the concentration of inhibitor protein X in said sample; and (c) comparing said concentration as determined in step (b) with the norm inhibitor protein X concentration associated with serum of cancer-free patients, whereby a significant reduction of inhibitor protein X concentration relative to the norm concentration indicates the probability of cancer.
Claim 2
Independent Claim
78 words
A method for detecting cancer in humans which comprises the steps of (a) obtaining a blood sample from a patient to be screened for cancer; (b) determining the concentration of inhibitor protein X in said sample; and (c) comparing said concentration as determined in step (b) with the norm inhibitor protein X concentration associated with serum of cancer-free patients, whereby a significant reduction of inhibitor protein X concentration relative to the norm concentration indicates the probability of cancer.
Claim 3
Independent Claim
88 words
A method for detecting cancer in humans which comprises the steps of (a) obtaining a blood sample from a patient to be screened for cancer; (b) determining the concentration of inhibitor protein X in said sample required to inhibit 50% of bleomycin-induced degradation of PM-2 DNA; and (c) comparing said IC 50 value as determined in step (b) with the norm IC 50 value associated with serum of cancer-free patients, whereby a significant elevation of said IC 50 value from the norm value indicates the probability of cancer.
Claim 4
Independent Claim
88 words
A method for detecting cancer in humans which comprises the steps of (a) obtaining a blood sample from a patient to be screened for cancer; (b) determining the concentration of inhibitor protein X in said sample required to inhibit 50% of bleomycin-induced degradation of PM-2 DNA; and (c) comparing said IC 50 value as determined in step (b) with the norm IC 50 value associated with serum of cancer-free patients, whereby a significant elevation of said IC 50 value from the norm value indicates the probability of cancer.
Claim 5
Dependent Claim
171 words
The method according to claim 2 wherein determination of the IC 50 value in step (b) is made by the steps of (1) preparing a mixture of the blood sample with a solution of bleomycin, PM-2 DNA and 2-mercaptoethanol in pH 9.5 buffer; (2) incubating the mixture from step (1) for 30 minutes as a temperature of 37° C.; (3) adding an aliquot of the mixture from step (2) to a mixture of ethidium bromide in a pH 12.1 denaturation buffer; (4) determining the fluoroescence of the ethidium bromide: PM-2 DNA mixture from step (3) with a spectrophotofluorometer at 530 nm excitation and 590 nm emission; (5) determining the percent inhibition of bleomycin-induced PM-2 DNA degradation from the change in fluorescence of the sample relative to a control sample containing no bleomycin: (6) determining the concentration of inhibitor protein X by the Lowry method; and (7) determining from the values obtained in steps (5) and (6) the concentration of inhibitor protein X required to inhibit 50% of bleomycin-induced PM-2 DNA degradation.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-06-01 | 1984-12-01 | 1985-06-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-06-01 | 1988-12-01 | 1989-06-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-06-01 | 1992-12-01 | 1993-06-02 | $7700.00 | Window Closed / Lapsed |